The discovery of the nephrogenic systemic fibrosis (NSF) and its link with the dissociation of certain Gd(III)-based contrast agents (CAs) applied in the magnetic resonance imaging (MRI) induced a still growing research to replace the compromised agents with safer alternatives. In recent years, several ligands were designed to exploit the luminescence properties of the lanthanides, containing structurally constrained aromatic moieties, which may form rigid Gd(III) complexes. One of these ligands is (1,10-phenanthroline-2,9-diyl)bis(methyliminodiacetic acid) (HFENTA) designed and synthesized to sensitize Eu(III) and Tb(III) luminescence.
View Article and Find Full Text PDF